Pfizer Still Trades Over $26 as RBC Lift Balances Out Drug-Pricing Concerns
Pfizer shares edged up 0.36% to $26.27 Friday after RBC Capital upgraded the stock to Sector Perform, citing a more balanced risk-reward and maintaining a $25 price target; investors now await key 2026 oncology trial readouts, while European drug-pricing pressure remains a significant risk.